Use access key #2 to skip to page content.
$5.71 -0.34 (-5.62%)
8/21/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

2

Avatar bluedough (< 20) Submitted: 8/29/06 4:59 PM : Outperform Start Price: $8.42 EXEL Score: -30.52

I like EXEL as a speculative pick in biotech because unlike some other ridiculous companies, EXEL HAS THEIR NOSE TO THE GRINDSTONE actually doing something with their cash burn. Even getting a drug to phase II is no small feat, and they have a pipeline of such drugs. Lets hope for our sake, and for the poor cancer patients, that they see great success.

Report this Post Replies: 0 | Reply

Featured Broker Partners